DRG Epidemiology’s coverage of acute respiratory distress syndrome (ARDS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of ARDS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

DRG Epidemiology’s ARDS forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ARDS over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following ARDS subpopulations:

  • Diagnosed incident events.
  • Diagnosed incident events by severity.
  • Diagnosed incidents events by type of pulmonary injury.
  • Diagnosed incident events of sepsis-related versus non-sepsis-related ARDS.

Note: Coverage may vary by country.

Table of contents

  • Acute Respiratory Distress Syndrome - Epidemiology - Mature Markets Data

Author(s): Dr. Ravdeep Kaur, MPH; Alison Isherwood, MSc, MRes, PhD

Ravdeep Kaur started working in Decision Resources Inc. as an associate epidemiologist since December 31st, 2015.

She performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period.

She produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets.

She holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from Rajiv Gandhi University of Health Sciences, India. She also has a Fellowship in Heath care Technology Assessment from World health Organization (WHO), India office.

 Prior to joining Decision Resources, Ravdeep worked as a Consultant in Reproductive, Maternal, Child and Adolescent Health Program in a United States Agency for International development (USAID) funded project.   

Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.


Related Reports

Biosimilars - Market Events And Forecast - Respiratory

In 2018, sales of branded biologics in respiratory indications exceeded $1.5 billion across the major markets (United States, EU5, and Japan)....

View Details

Allergic Rhinitis - Special Topics - Allergic Respiratory Disorders | Special Topics | US

Allergic respiratory disorders—such as allergic rhinitis, chronic rhinosinusitis, and nasal polyps—are characterized by activation of inflammatory pathways and the production of immunog...

View Details